Intelligence Report · ~12 min read
AstraZeneca Intelligence Report
Generated from 8 signals · 8 evidence sources
Type
Company Intelligence ReportGenerated
Jun 10, 2026
Confidence
Low Confidence · 55%
Evidence
42 items
Sources
42
Executive Summary
Synthesized assessment from linked signals, findings, and evidence relationships.
AstraZeneca maintains an active intelligence profile across Pulmonary Arterial Hypertension, Prostacyclin Analog, Oncology, Liver Cancer, Rare Diseases. 8 signals are linked with 6 investigate-priority items requiring leadership attention. Competitive pressure is low with high portfolio impact. Evidence coverage stands at 72% across 8 tracked sources. Highest-priority development: Enhertu recommended in EU for HER2+ solid tumours. Portfolio development. Enhertu recommended in EU for HER2+ solid tumours is an owned AstraZeneca portfolio development in Oncology · HER2-positive solid tumours.
Key Developments
Material intelligence events ranked by strategic relevance.
- investigateJun 1, 2026
Breztri Gains US Approval as First Triple Therapy for Asthma
Respiratory · Asthma · opportunity score 57
View detail - investigateJun 2, 2026
Efzimfotase alfa shows positive Phase III results in hypophosphatasia
Rare Diseases · Hypophosphatasia · opportunity score 56
View detail - investigateJun 2, 2026
Imfinzi+Imjudo shows significant PFS improvement in early liver cancer trial
Oncology · Liver Cancer · opportunity score 50
View detail - investigateJun 2, 2026
Enhertu recommended for EU approval in HER2+ metastatic solid tumours
Oncology · HER2-positive solid tumours · opportunity score 50
View detail - investigateJun 1, 2026
AstraZeneca's Baxfendy Receives US Approval for Hypertension as First-in-Class Treatment
Cardiology · Hypertension · opportunity score 50
View detail - investigateJun 2, 2026
Tozorakimab achieves primary endpoints in Phase III trials for COPD
Respiratory · COPD · opportunity score 46
View detail - portfolio
Enhertu recommended in EU for HER2+ solid tumours
FDA approval
View detail - portfolio
AstraZeneca's Baxfendy Receives US Approval for Hypertension as First-in-Class Treatment
FDA approval
View detail - portfolio
Imfinzi+Imjudo improves PFS in early liver cancer
Phase III success
View detail - portfolio
Enhertu approved in two HER2+ early BC settings
FDA approval
View detail - portfolio
Tozorakimab achieves primary endpoints in Phase III trials for COPD
Acquisition
View detail - portfolio
Third tozorakimab positive Phase III in COPD
Phase III success
View detail
Strategic Implications
Portfolio and competitive decisions informed by this intelligence profile.
Opportunity score 404 with buyer quality 10 (Enterprise). Competitive pressure: Low. Portfolio impact: High. 6 investigate-priority signals warrant near-term portfolio review.
Supporting Evidence
Evidence-backed items with source attribution and confidence disclosure.
Enhertu recommended in EU for HER2+ solid tumours
Low Confidence · 0%FDA approval
Source: AstraZeneca, AstraZeneca, Portfolio
View evidenceAstraZeneca's Baxfendy Receives US Approval for Hypertension as First-in-Class Treatment
Low Confidence · 0%FDA approval
Source: Humanexa Signals, FDA, Portfolio
View evidenceImfinzi+Imjudo improves PFS in early liver cancer
Low Confidence · 0%Phase III success
Source: AstraZeneca, AstraZeneca, Portfolio
View evidenceEnhertu approved in two HER2+ early BC settings
Low Confidence · 0%FDA approval
Source: AstraZeneca, AstraZeneca, Portfolio
View evidenceTozorakimab achieves primary endpoints in Phase III trials for COPD
Low Confidence · 0%Acquisition
Source: AstraZeneca, ClinicalTrials.gov, Portfolio
View evidenceThird tozorakimab positive Phase III in COPD
Low Confidence · 0%Phase III success
Source: AstraZeneca, AstraZeneca, Portfolio
View evidenceEfzimfotase alfa Ph3 program show positive results
Low Confidence · 0%Phase III success
Source: AstraZeneca, AstraZeneca, Portfolio
View evidenceTozorakimab met OBERON/TITANIA primary endpoints
Low Confidence · 0%Phase III success
Source: AstraZeneca, AstraZeneca, Portfolio
View evidenceClass 2 Medicines Recall: Sterling Pharmaceuticals Ltd (specials manufacturer MS 32515), KidNaps (Melatonin) 1mg in 1ml Oral Solution, EL(26)A/09
Moderate Confidence · 72%Regulatory precedent may inform portfolio positioning
Source: MHRA, MHRA, Regunera
View evidenceClass 3 Medicines Recall: Aspar Pharmaceuticals Ltd, Ibuprofen 200mg Tablets, Ibucalm 200mg tablets, EL(26)A/07
Moderate Confidence · 72%Regulatory precedent may inform portfolio positioning
Source: MHRA, MHRA, Regunera
View evidenceRisk of severe harm from use of incorrect giving (administration) set for blood transfusion (DSI/2026/003)
Moderate Confidence · 72%Regulatory precedent may inform portfolio positioning
Source: MHRA, MHRA, Regunera
View evidenceProject Orbis
Moderate Confidence · 72%Regulatory precedent may inform portfolio positioning
Source: MHRA, MHRA, Regunera
View evidence[SHINSA]The new website “Designation / Early Access“ launched.
Moderate Confidence · 72%Regulatory precedent may inform portfolio positioning
Source: PMDA, PMDA, Regunera
View evidence[SHINSA]Four English-language Early Considerations have been published, including those on biosimilars, in vivo diagnostics, and vaccines.
Moderate Confidence · 72%Regulatory precedent may inform portfolio positioning
Source: PMDA, PMDA, Regunera
View evidenceFDA AP — BAXFENDY (ORIG)
Moderate Confidence · 77%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidenceFDA AP — BAXFENDY (ORIG)
Moderate Confidence · 77%Regulatory precedent may inform portfolio positioning
Source: FDA, FDA, Regunera
View evidence
Related Intelligence
Deep links to signals, insights, companies, and assets in the Humanexa graph.
Signals
- Breztri Gains US Approval as First Triple Therapy for Asthma
Respiratory · Asthma
- Efzimfotase alfa shows positive Phase III results in hypophosphatasia
Rare Diseases · Hypophosphatasia
- FDA Accepts Supplement Application for Tyvaso (Treprostinil)
Pulmonary Arterial Hypertension · Prostacyclin Analog
- Imfinzi+Imjudo shows significant PFS improvement in early liver cancer trial
Oncology · Liver Cancer
- Enhertu recommended for EU approval in HER2+ metastatic solid tumours
Oncology · HER2-positive solid tumours
- AstraZeneca's Baxfendy Receives US Approval for Hypertension as First-in-Class Treatment
Cardiology · Hypertension
- Tozorakimab achieves primary endpoints in Phase III trials for COPD
Respiratory · COPD
- Study on NMES for Functional Recovery in COPD and Pneumonia Patients
Respiratory · COPD